Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Craig T. Wallington‐Beddoe"'
Desmoglein‐2 expression is an independent predictor of poor prognosis patients with multiple myeloma
Autor:
Lisa M. Ebert, Kate Vandyke, M. Zahied Johan, Mark DeNichilo, Lih Y. Tan, Kay K. Myo Min, Benjamin M. Weimann, Brenton W. Ebert, Stuart M. Pitson, Andrew C. W. Zannettino, Craig T. Wallington‐Beddoe, Claudine S. Bonder
Publikováno v:
Molecular Oncology, Vol 16, Iss 6, Pp 1221-1240 (2022)
Multiple myeloma (MM) is the second most common haematological malignancy and is an incurable disease of neoplastic plasma cells (PC). Newly diagnosed MM patients currently undergo lengthy genetic testing to match chromosomal mutations with the most
Externí odkaz:
https://doaj.org/article/3c6fe6a110d5445e84fcd27cd4ff16e5
Autor:
Melissa K. Bennett, Manjun Li, Melinda N. Tea, Melissa R. Pitman, John Toubia, Paul P.-S. Wang, Dovile Anderson, Darren J. Creek, Robert Z. Orlowski, Briony L. Gliddon, Jason A. Powell, Craig T. Wallington-Beddoe, Stuart M. Pitson
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 24, Iss 1, Pp 1-11 (2022)
The introduction of the proteasome inhibitor bortezomib into treatment regimens for myeloma has led to substantial improvement in patient survival. However, whilst bortezomib elicits initial responses in many myeloma patients, this haematological mal
Externí odkaz:
https://doaj.org/article/f5e0bdd9d3004cfdbf70bbe296a47fe3
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-15 (2021)
Abstract New approaches to stratify multiple myeloma patients based on prognosis and therapeutic decision-making, or prediction, are needed since patients are currently managed in a similar manner regardless of individual risk factors or disease char
Externí odkaz:
https://doaj.org/article/432b03f4341e4395befe3c2cda9a3c57
Publikováno v:
Cell Death Discovery, Vol 7, Iss 1, Pp 1-2 (2021)
Externí odkaz:
https://doaj.org/article/077989e5aad04eda9e4096e1c9555fed
Publikováno v:
Biomarker Research, Vol 6, Iss 1, Pp 1-7 (2018)
Abstract Background Sphingosine kinase (SphK) 2 has been implicated in the development of a range of cancers and inhibitors of this enzyme are currently in clinical trial. We have previously demonstrated a role for SphK2 in the development of acute l
Externí odkaz:
https://doaj.org/article/74c507326aba49c68b3c108f208a09e2
Autor:
Craig T. Wallington-Beddoe, Anthony S. Don, John Hewson, Qiao Qiao, Rachael A. Papa, Richard B. Lock, Kenneth F. Bradstock, Linda J. Bendall
Publikováno v:
PLoS ONE, Vol 7, Iss 8 (2012)
Externí odkaz:
https://doaj.org/article/84bc8cfb3b8d4c95b5ffd9efd32994fa
Autor:
Linda J. Bendall, Kenneth F. Bradstock, Stuart M. Pitson, Daochen Tong, Jason A. Powell, Craig T. Wallington-Beddoe
PDF file - 1070KB, Supplementary methods, Tables S1-S5 and Figures S1-S14 Table S1. Patient Information Table S2. Primers. Table S3. Regulation of c-Myc Target Genes by SK2 Inhibition Table S4. Gene Enrichment Analysis for All Nine Cell Lines. Table
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11513e414baa7bd433e9376585a9ad44
https://doi.org/10.1158/0008-5472.22399805
https://doi.org/10.1158/0008-5472.22399805
Autor:
Briony L. Gliddon, Craig T. Wallington-Beddoe, Manjun Li, Darren J. Creek, Melissa R. Pitman, Melinda N. Tea, Paul Wang, Dovile Anderson, John Toubia, Melissa K. Bennett, Robert Z. Orlowski, Stuart M. Pitson, Jason A. Powell
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 24, Iss 1, Pp 1-11 (2022)
Neoplasia (New York, N.Y.)
Neoplasia (New York, N.Y.)
Refereed/Peer-reviewed The introduction of the proteasome inhibitor bortezomib into treatment regimens for myeloma has led to substantial improvement in patient survival. However, whilst bortezomib elicits initial responses in many myeloma patients,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c4372e540234dd54ec39b9af964b760
http://www.sciencedirect.com/science/article/pii/S1476558621000993
http://www.sciencedirect.com/science/article/pii/S1476558621000993
Autor:
Krystal Bergin, Andrew Spencer, Anna Kalff, Shreerang Sirdesai, John V. Reynolds, Craig T. Wallington-Beddoe, Flora Yuen
Publikováno v:
British Journal of Haematology. 194:580-586
We evaluated the efficacy and tolerability of continuous ixazomib-thalidomide-dexamethasone (ITd: 4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly). A total of 39 patients with relapsed/refractory multiple myeloma (RRMM) aged ≥18 years with one t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::256f8dc735605aa13fba5f7230335ccd
https://doi.org/10.1111/bjh.17504
https://doi.org/10.1111/bjh.17504
Publikováno v:
ACS Pharmacol Transl Sci
The aim of this study is to determine whether manipulation of the drug transporter P-glycoprotein improves the efficacy of proteasome inhibitors in multiple myeloma cells. P-glycoprotein is a well-known drug transporter that is associated with chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ac308ad9727f55a7a15c7b56a08f68e
https://doi.org/10.1021/acsptsci.0c00200
https://doi.org/10.1021/acsptsci.0c00200